XTX Topco Ltd Acquires 17,536 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

XTX Topco Ltd grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 138.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,215 shares of the company's stock after purchasing an additional 17,536 shares during the quarter. XTX Topco Ltd's holdings in IDEAYA Biosciences were worth $495,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of IDYA. CWM LLC boosted its stake in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after purchasing an additional 1,814 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at approximately $47,000. Signaturefd LLC raised its position in shares of IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after acquiring an additional 2,271 shares during the period. Exchange Traded Concepts LLC raised its position in shares of IDEAYA Biosciences by 46.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $109,000 after acquiring an additional 2,112 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in shares of IDEAYA Biosciences by 33.2% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company's stock valued at $189,000 after acquiring an additional 2,884 shares during the period. Institutional investors own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IDYA. TD Cowen began coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a research report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a research report on Monday, July 28th. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their price target for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. Finally, The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a research report on Thursday, July 10th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $48.09.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $22.41 on Friday. The company has a market capitalization of $1.96 billion, a P/E ratio of -5.91 and a beta of 0.09. The company's 50 day moving average price is $22.42 and its two-hundred day moving average price is $20.38. IDEAYA Biosciences, Inc. has a 52 week low of $13.45 and a 52 week high of $40.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. The firm's quarterly revenue was up NaN% on a year-over-year basis. During the same period in the prior year, the company earned ($0.68) earnings per share. Analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.